Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 8/2017

01-08-2017 | Review Article

Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature

Authors: Gonçalo Boleto, Moustapha Dramé, Isabelle Lambrecht, Jean-Paul Eschard, Jean-Hugues Salmon

Published in: Clinical Rheumatology | Issue 8/2017

Login to get access

Abstract

The aim of this study was to evaluate the structural effect of denosumab on patients with rheumatoid arthritis (RA). We performed a systematic review of the literature in the following databases: PubMed, Cochrane, Web of Science, ClinicalTrials.​gov, and the WHO International Clinical Trials Registry Platform. All studies evaluating the structural effect of denosumab on RA and meeting predefined criteria were included. Data regarding disease activity, progression of joint damage, joint space narrowing, and safety were recorded. Among 168 studies identified, only 4 were finally included in this review, involving a total of 687 patients. These 4 studies showed that denosumab is effective on joint damage at 6 and 12 months as compared to placebo, alendronate, and biological disease-modifying anti-rheumatic drugs (bDMARDs) alone. No effect was observed in terms of joint space narrowing, and DAS28 and HAQ scores remained unchanged. No case of osteonecrosis of the jaw or atypical fracture was recorded, and safety was similar in both denosumab and control groups. Denosumab appears to be effective on joint erosion at 6 and 12 months in patients with RA meeting the ACR criteria, treated or not by a biologic, with excellent safety.
Literature
1.
Furst DE, Emery P (2014) Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets. Rheumatol Oxf Engl. 53(9):1560–1569CrossRef
2.
3.
Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS (2005) Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1(1):47–54CrossRefPubMed
4.
5.
Pettit AR, Ji H, von Stechow D, Müller R, Goldring SR, Choi Y et al (2001) TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159(5):1689–1699CrossRefPubMedPubMedCentral
6.
7.
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765CrossRefPubMed
8.
Orwoll E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL et al (2012) A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 97(9):3161–3169CrossRefPubMed
9.
Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TLJ, Saad F et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361(8):745–755CrossRefPubMedPubMedCentral
10.
Takahashi K, Setoguchi T, Tawaratsumida H, Arishima Y, Tominaga H, Ishidou Y et al (2015) Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics. BMC Musculoskelet Disord 16:269CrossRefPubMedPubMedCentral
11.
Hoes JN, Bultink IEM, Lems WF (2015) Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother 16(4):559–571CrossRefPubMed
12.
Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299–1309CrossRefPubMed
13.
Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L et al (2010) Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 69(5):872–875CrossRefPubMed
14.
Deodhar A, Dore RK, Mandel D, Schechtman J, Shergy W, Trapp R et al (2010) Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res 62(4):569–574CrossRef
15.
Sharp JT, Tsuji W, Ory P, Harper-Barek C, Wang H, Newmark R (2010) Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res 62(4):537–544CrossRef
16.
17.
Døhn UM, Ejbjerg BJ, Hasselquist M, Narvestad E, Møller J, Thomsen HS et al (2008) Detection of bone erosions in rheumatoid arthritis wrist joints with magnetic resonance imaging, computed tomography and radiography. Arthritis Res Ther. 10(1):R25CrossRefPubMedPubMedCentral
18.
Fouque-Aubert A, Boutroy S, Marotte H, Vilayphiou N, Bacchetta J, Miossec P et al (2010) Assessment of hand bone loss in rheumatoid arthritis by high-resolution peripheral quantitative CT. Ann Rheum Dis 69(9):1671–1676CrossRefPubMed
19.
20.
PICO ontology | Cochrane Linked Data [Internet]. [cited 2017 Feb 19]. Available from: /pico-ontology
21.
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324CrossRefPubMed
22.
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581CrossRefPubMed
23.
Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M et al (1985) How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 28(12):1326–1335CrossRefPubMed
24.
van der Heijde D (2000) How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 27(1):261–263PubMed
25.
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48CrossRefPubMed
26.
Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735CrossRefPubMed
27.
Ramey DR, Raynauld JP, Fries JF (1992) The health assessment questionnaire 1992: status and review. Arthritis Care Res Off J Arthritis Health Prof Assoc 5(3):119–129CrossRef
28.
29.
Takeuchi T, Tanaka Y, Ishiguro N, Yamanaka H, Yoneda T, Ohira T et al (2015) Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone erosion (DRIVE)—a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis 19
30.
Yue J (2016) Repair of bone erosion in rheumatoid arthritis by denosumab: a high-resolution peripheral quantitative computed tomography study. Arthritis Care Res Hoboken
31.
Hasegawa T, Kaneko Y, Izumi K, Takeuchi T (2016) Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis. Jt Bone Spine Rev Rhum. 28
32.
Gaujoux-Viala C, Paternotte S, Combe B, Dougados M (2012) Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort. Rheumatol Oxf Engl 51(9):1648–1654CrossRef
33.
Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I (2005 Nov) Low-dose prednisolone in addition to the initial disease-modifying anti-rheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial. Arthritis Rheum 52(11):3360–3370CrossRefPubMed
34.
35.
Koike T, Inui K (2015) How can the treatment of rheumatoid arthritis be improved in Japan? Int J Clin Rheumatol 10(4):235–244CrossRef
36.
Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509CrossRefPubMed
37.
Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 68(1):1–25CrossRef
38.
Mok CC, Tam LS, Chan TH, Lee GKW, Li EKM (2011) Hong Kong Society of Rheumatology. Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol 30(3):303–312CrossRefPubMed
39.
Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME (2014) Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev 6:CD000957
40.
41.
Sharp JT, Wolfe F, Mitchell DM, Bloch DA (1991) The progression of erosion and joint space narrowing scores in rheumatoid arthritis during the first twenty-five years of disease. Arthritis Rheum 34(6):660–668CrossRefPubMed
42.
Smolen JS, Van Der Heijde DMFM, St Clair EW, Emery P, Bathon JM, Keystone E et al (2006) Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 54(3):702–710CrossRefPubMed
43.
Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D et al (2009) Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 68(10):1535–1340CrossRefPubMed
44.
Breuil V, Euller-Ziegler L (2006) Bisphosphonate therapy in rheumatoid arthritis. Jt Bone Spine Rev Rhum 73(4):349–354CrossRef
45.
Le Goff B, Soltner E, Charrier C, Maugars Y, Rédini F, Heymann D et al (2009) A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis. Arthritis Res Ther 11(6):185CrossRef
46.
Jarrett SJ, Conaghan PG, Sloan VS, Papanastasiou P, Ortmann C-E, O’Connor PJ et al (2006) Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum 54(5):1410–1414CrossRefPubMed
47.
Valleala H, Laasonen L, Koivula M-K, Risteli J, Konttinen YT (2012) Effect of oral clodronate on structural damage and bone turnover in rheumatoid arthritis. Clin Exp Rheumatol 30(1):114–117PubMed
48.
Genovese MC, Cohen S, Moreland L, Lium D, Robbins S, Newmark R et al (2004) Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 50(5):1412–1419CrossRefPubMed
49.
Curtis JR, Xie F, Yun H, Saag KG, Chen L, Delzell E (2015) Risk of hospitalized infection among rheumatoid arthritis patients concurrently treated with a biologic agent and denosumab. Arthritis Rheumatol Hoboken NJ 67(6):1456–1464CrossRef
Metadata
Title
Disease-modifying anti-rheumatic drug effect of denosumab on radiographic progression in rheumatoid arthritis: a systematic review of the literature
Authors
Gonçalo Boleto
Moustapha Dramé
Isabelle Lambrecht
Jean-Paul Eschard
Jean-Hugues Salmon
Publication date
01-08-2017
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2017
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-017-3722-6

Other articles of this Issue 8/2017

Clinical Rheumatology 8/2017 Go to the issue

Original Article

Uric acid is independent cardiovascular risk factor, as manifested by increased carotid intima-media thickness in rheumatoid arthritis patients

Original Article

Ambroxol for fibromyalgia: one group pretest-posttest open-label pilot study

Erratum

Erratum to: Expression of CCR6 on B cells in systemic lupus erythematosus patients

Original Article

Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents

Original Article

Risk factors of flare in rheumatoid arthritis patients with both clinical and ultrasonographic remission: a retrospective study from China

Original Article

Serum prolidase activity in systemic sclerosis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits